The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Seizures and Epileptiform Activity in the Early Stages of Alzheimer Disease
Open accessAbstract
IMPORTANCE: Epileptic activity associated with Alzheimer disease (AD) deserves increased attention because it has a harmful impact on these patients, can easily go unrecognized and untreated, and may reflect pathogenic processes that also contribute to other aspects of the illness. We report key features of AD-related seizures and epileptiform activity that are instructive for clinical practice and highlight similarities between AD and transgenic animal models of the disease. OBJECTIVE: To describe common clinical characteristics and treatment outcomes of patients with amnestic mild cognitive impairment (aMCI) or early AD who also have epilepsy or subclinical epileptiform activity. DESIGN: Retrospective observational study from 2007 to 2012. SETTING Memory and Aging Center, University of California, San Francisco. PATIENTS: We studied 54 patients with a diagnosis of aMCI plus epilepsy (n = 12), AD plus epilepsy (n = 35), and AD plus subclinical epileptiform activity (n = 7). MAIN OUTCOMES AND MEASURES: Clinical and demographic data, electroencephalogram (EEG) readings, and treatment responses to antiepileptic medications. RESULTS: Patients with aMCI who had epilepsy presented with symptoms of cognitive decline 6.8 years earlier than patients with aMCI who did not have epilepsy (64.3 vs 71.1 years; P = .02). Patients with AD who had epilepsy presented with cognitive decline 5.5 years earlier than patients with AD who did not have epilepsy (64.8 vs 70.3 years; P = .001). Patients with AD who had subclinical epileptiform activity also had an early onset of cognitive decline (58.9 years). The timing of seizure onset in patients with aMCI and AD was nonuniform (P < .001), clustering near the onset of cognitive decline. Epilepsies were most often complex partial seizures (47%) and more than half were nonconvulsive (55%). Serial or extended EEG monitoring appeared to be more effective than routine EEG at detecting interictal and subclinical epileptiform activity. Epileptic foci were predominantly unilateral and temporal. Of the most commonly prescribed antiepileptics, treatment outcomes appeared to be better for lamotrigine and levetiracetam than for phenytoin. CONCLUSIONS AND RELEVANCE: Common clinical features of patients with aMCI- or AD-associated epilepsy at our center included early age at onset of cognitive decline, early incidence of seizures in the disease course, unilateral temporal epileptic foci detected by serial/extended EEG, transient cognitive dysfunction, and good seizure control and tolerability with lamotrigine and levetiracetam. Careful identification and treatment of epilepsy in such patients may improve their clinical course.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Winblad, B., Palmer, K., Kivipelto, M., Jelic, V., Fratiglioni, L., Wahlund, L. ‐., Nordberg, A., Bäckman, L., Albert, M., Almkvist, O., et al. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01380.x · Cited by 4,946
Berg, A. T., Berkovic, S. F., Brodie, M. J., Buchhalter, J., Cross, J. H., Van Emde Boas, W., Engel, J., French, J., Glauser, T. A., Mathern, G. W., et al. (2010) · Epilepsia · doi:10.1111/j.1528-1167.2010.02522.x · Cited by 4,363
Fisher, R. S., Boas, W. V. E., Blume, W., Elger, C., Genton, P., Lee, P., & Engel, J. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.66104.x · Cited by 3,671
Beghi, E., Berg, A., Carpio, A., Forsgren, L., Hesdorffer, D. C., Hauser, W. A., Malmgren, K., Shinnar, S., Temkin, N., Thurman, D., et al. (2005) · Epilepsia · doi:10.1111/j.1528-1167.2005.00273_1.x · Cited by 2,296
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,851
Palop, J. J., Chin, J., Roberson, E. D., Wang, J., Thwin, M. T., Bien-Ly, N., Yoo, J., Ho, K. O., Yu, G.-Q., Kreitzer, A., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.025 · Cited by 1,653
Self-citationAmyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
Self-citationMcKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 1,495
Cited by
Network abnormalities and interneuron dysfunction in Alzheimer disease
Palop, J. J., & Mucke, L. (2016) · Nature reviews. Neuroscience · doi:10.1038/nrn.2016.141 · Cited by 1,022
Self-citationβ-Hydroxybutyrate: A Signaling Metabolite
Newman, J. C., & Verdin, E. (2017) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071816-064916 · Cited by 872
A vicious cycle of β amyloid−dependent neuronal hyperactivation
Zott, B., Simon, M. M., Hong, W., Unger, F., Chen-Engerer, H.-J., Frosch, M. P., Sakmann, B., Walsh, D. M., & Konnerth, A. (2019) · Science · doi:10.1126/science.aay0198 · Cited by 640
Epileptic activity in Alzheimer’s disease: Causes and clinical relevance
Vossel, K. A., Tartaglia, M. C., Nygaard, H. B., Zeman, A. Z., & Miller, B. L. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30044-3 · Cited by 590
Self-citationThe road to restoring neural circuits for the treatment of Alzheimer's disease
Canter, R. G., Penney, J., & Tsai, L.-H. (2016) · Nature · doi:10.1038/nature20412 · Cited by 565
A genetic cause of Alzheimer disease: mechanistic insights from Down syndrome
Wiseman, F. K., Al-Janabi, T., Hardy, J., Karmiloff-Smith, A., Nizetic, D., Tybulewicz, V. L. J., Fisher, E. M. C., & Strydom, A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3983 · Cited by 562
Incidence and impact of subclinical epileptiform activity in Alzheimer’s disease.
Vossel, K. A., Ranasinghe, K. G., Beagle, A. J., Mizuiri, D., Honma, S. M., Dowling, A. F., Darwish, S. M., Van Berlo, V., Barnes, D. E., Mantle, M., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24794 · Cited by 557
Self-citationGonzález-Reyes, R. E., Nava-Mesa, M. O., Vargas-Sánchez, K., Ariza-Salamanca, D., & Mora-Muñoz, L. (2017) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2017.00427 · Cited by 527
Nicotinic ACh receptors as therapeutic targets in CNS disorders
Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 450
Ferreira, S. T., Lourenco, M. V., Oliveira, M. M., & De Felice, F. G. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00191 · Cited by 373
Sen, A., Jette, N., Husain, M., & Sander, J. W. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33064-8 · Cited by 369
Schultz, A. P., Chhatwal, J. P., Hedden, T., Mormino, E. C., Hanseeuw, B. J., Sepulcre, J., Huijbers, W., LaPoint, M., Buckley, R. F., Johnson, K. A., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3263-16.2017 · Cited by 330
Šišková, Z., Justus, D., Kaneko, H., Friedrichs, D., Henneberg, N., Beutel, T., Pitsch, J., Schoch, S., Becker, A., von der Kammer, H., et al. (2014) · Neuron · doi:10.1016/j.neuron.2014.10.024 · Cited by 320
Imbalance between firing homeostasis and synaptic plasticity drives early-phase Alzheimer’s disease
Styr, B., & Slutsky, I. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0080-x · Cited by 318
Jeremic, D., Jiménez-Díaz, L., & Navarro-López, J. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101496 · Cited by 306
Antisense Reduction of Tau in Adult Mice Protects against Seizures
DeVos, S. L., Goncharoff, D. K., Chen, G., Kebodeaux, C. S., Yamada, K., Stewart, F. R., Schuler, D. R., Maloney, S. E., Wozniak, D. F., Rigo, F., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-13.2013 · Cited by 311
“This AD-associated excitotoxicity has been implicated in the pathogenesis of the disease (Olney et al., 1997; Mattson, 2004) and has recently been linked to an earlier onset of cognitive decline in AD patients (Vossel et al., 2013).”
BackgroundRole of Amyloid-β and Tau Proteins in Alzheimer’s Disease: Confuting the Amyloid Cascade
Gulisano, W., Maugeri, D., Baltrons, M. A., Fà, M., Amato, A., Palmeri, A., D’Adamio, L., Grassi, C., Devanand, D. P., Honig, L. S., et al. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179935 · Cited by 313
“However, although an increase of brain activity in AD could be supported by data indicating hyperexcitability in transgenic mice and human AD patients [139, 140], this activity-dependent role of Aβ should be better viewed as a physiological mechanism occurring within the healthy brain, especially because levels of Aβ…”
BackgroundNovak, P., Schmidt, R., Kontsekova, E., Zilka, N., Kovacech, B., Skrabana, R., Vince-Kazmerova, Z., Katina, S., Fialova, L., Prcina, M., et al. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30331-3 · Cited by 304
Babiloni, C., Blinowska, K., Bonanni, L., Cichocki, A., De Haan, W., Del Percio, C., Dubois, B., Escudero, J., Fernández, A., Frisoni, G., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2019.09.008 · Cited by 284
Alzheimer’s disease brain-derived extracellular vesicles spread tau pathology in interneurons
Ruan, Z., Pathak, D., Venkatesan Kalavai, S., Yoshii-Kitahara, A., Muraoka, S., Bhatt, N., Takamatsu-Yukawa, K., Hu, J., Wang, Y., Hersh, S., et al. (2021) · Brain · doi:10.1093/brain/awaa376 · Cited by 283
Cognition and dementia in older patients with epilepsy
Sen, A., Capelli, V., & Husain, M. (2018) · Brain · doi:10.1093/brain/awy022 · Cited by 280
Vossel, K., Ranasinghe, K. G., Beagle, A. J., La, A., Ah Pook, K., Castro, M., Mizuiri, D., Honma, S. M., Venkateswaran, N., Koestler, M., et al. (2021) · JAMA Neurology · doi:10.1001/jamaneurol.2021.3310 · Cited by 271
Self-citationNeuronal hyperactivity--A key defect in Alzheimer’s disease?
Busche, M. A., & Konnerth, A. (2015) · BioEssays · doi:10.1002/bies.201500004 · Cited by 266
Senatorov, V. V., Friedman, A. R., Milikovsky, D. Z., Ofer, J., Saar-Ashkenazy, R., Charbash, A., Jahan, N., Chin, G., Mihaly, E., Lin, J. M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw8283 · Cited by 257
Bi, D., Wen, L., Wu, Z., & Shen, Y. (2020) · Alzheimer's & Dementia · doi:10.1002/alz.12088 · Cited by 232
Modifiable Risk Factors for Alzheimer’s Disease
Edwards III, G. A., Gamez, N., Escobedo Jr., G., Calderon, O., & Moreno-Gonzalez, I. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00146 · Cited by 253
Ghatak, S., Dolatabadi, N., Trudler, D., Zhang, X., Wu, Y., Mohata, M., Ambasudhan, R., Talantova, M., & Lipton, S. A. (2019) · eLife · doi:10.7554/elife.50333 · Cited by 227
Hijazi, S., Heistek, T. S., Scheltens, P., Neumann, U., Shimshek, D. R., Mansvelder, H. D., Smit, A. B., & van Kesteren, R. E. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0483-4 · Cited by 216
Early neuronal accumulation of DNA double strand breaks in Alzheimer’s disease
Shanbhag, N. M., Evans, M. D., Mao, W., Nana, A. L., Seeley, W. W., Adame, A., Rissman, R. A., Masliah, E., & Mucke, L. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0723-5 · Cited by 214
Self-citationLipid-accumulated reactive astrocytes promote disease progression in epilepsy
Chen, Z.-P., Wang, S., Zhao, X., Fang, W., Wang, Z., Ye, H., Wang, M.-J., Ke, L., Huang, T., Lv, P., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01288-6 · Cited by 214
Towards a Better Understanding of GABAergic Remodeling in Alzheimer’s Disease
Govindpani, K., Calvo-Flores Guzmán, B., Vinnakota, C., Waldvogel, H., Faull, R., & Kwakowsky, A. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18081813 · Cited by 208
Apolipoprotein E4, inhibitory network dysfunction, and Alzheimer’s disease
Najm, R., Jones, E. A., & Huang, Y. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-019-0324-6 · Cited by 183
Individuals with progranulin haploinsufficiency exhibit features of neuronal ceroid lipofuscinosis
Ward, M. E., Chen, R., Huang, H.-Y., Ludwig, C., Telpoukhovskaia, M., Taubes, A., Boudin, H., Minami, S. S., Reichert, M., Albrecht, P., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aah5642 · Cited by 193
Self-citationSelective Neuronal Vulnerability in Alzheimer’s Disease: A Network-Based Analysis
Roussarie, J.-P., Yao, V., Rodriguez-Rodriguez, P., Oughtred, R., Rust, J., Plautz, Z., Kasturia, S., Albornoz, C., Wang, W., Schmidt, E. F., et al. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.010 · Cited by 180
Beagle, A. J., Darwish, S. M., Ranasinghe, K. G., La, A. L., Karageorgiou, E., & Vossel, K. A. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170031 · Cited by 173
“Previous literature has indicated that seizures can precede or follow cognitive symptoms in both AD and non-AD dementias [4, 5, 31, 50, 51].”
Self-citationAssociation of epileptiform abnormalities and seizures in Alzheimer disease.
Lam, A. D., Sarkis, R. A., Pellerin, K. R., Jing, J., Dworetzky, B. A., Hoch, D. B., Jacobs, C. S., Lee, J. W., Weisholtz, D. S., Zepeda, R., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010612 · Cited by 172
“Seizures are reported in 10% to 22% of patients with AD(6) and may be a presenting symptom of the disease.(3,7,8) In patients with AD without seizures, subclinical epileptiform abnormalities were identified in 21% to 38%with the use of long-term scalp EEG recordings(9,10) and may be associated with accelerated cogniti…”
BackgroundLTP and memory impairment caused by extracellular Aβ and Tau oligomers is APP-dependent
Puzzo, D., Piacentini, R., Fá, M., Gulisano, W., Li Puma, D. D., Staniszewski, A., Zhang, H., Tropea, M. R., Cocco, S., Palmeri, A., et al. (2017) · eLife · doi:10.7554/elife.26991 · Cited by 172
Astrocyte calcium dysfunction causes early network hyperactivity in Alzheimer’s disease
Shah, D., Gsell, W., Wahis, J., Luckett, E. S., Jamoulle, T., Vermaercke, B., Preman, P., Moechars, D., Hendrickx, V., Jaspers, T., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111280 · Cited by 164
Harris, S. S., Wolf, F., De Strooper, B., & Busche, M. A. (2020) · Neuron · doi:10.1016/j.neuron.2020.06.005 · Cited by 161
Fogel, H., Frere, S., Segev, O., Bharill, S., Shapira, I., Gazit, N., O’Malley, T., Slomowitz, E., Berdichevsky, Y., Walsh, D. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.024 · Cited by 138
“…(Busche et al., 2008, 2012; Palop et al., 2007; Verret et al., 2012), in humans with mild cognitive impairments (Bakker et al., 2012), and in AD patients (Vossel et al., 2013), elucidating the synaptic mechanisms of hyperactivity is critical for understanding AD-associated cognitive impairments.”
BackgroundInfluentialPathogenic Tau Impairs Axon Initial Segment Plasticity and Excitability Homeostasis
Sohn, P. D., Huang, C. T.-L., Yan, R., Fan, L., Tracy, T. E., Camargo, C. M., Montgomery, K. M., Arhar, T., Mok, S.-A., Freilich, R., et al. (2019) · Neuron · doi:10.1016/j.neuron.2019.08.008 · Cited by 148
“Dysregulation of neuronal excitability underlies the cognitive impairment of neurodegenerative diseases characterized by tau inclusions (Dickerson et al., 2005; Olazaran et al., 2010; Vossel et al., 2013).”
BackgroundBhattacharjee, S., Zhao, Y., Dua, P., Rogaev, E. I., & Lukiw, W. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0150211 · Cited by 147
Tau reduction prevents disease in a mouse model of Dravet syndrome
Gheyara, A. L., Ponnusamy, R., Djukic, B., Craft, R. J., Ho, K., Guo, W., Finucane, M. M., Sanchez, P. E., & Mucke, L. (2014) · Annals of Neurology · doi:10.1002/ana.24230 · Cited by 138
Self-citationBlood-brain barrier leakage in Alzheimer’s disease: From discovery to clinical relevance
Nehra, G., Bauer, B., & Hartz, A. M. S. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108119 · Cited by 127
Horvath, A. A., Papp, A., Zsuffa, J., Szucs, A., Luckl, J., Radai, F., Nagy, F., Hidasi, Z., Csukly, G., Barcs, G., et al. (2021) · Clinical Neurophysiology · doi:10.1016/j.clinph.2021.03.050 · Cited by 125
Tang, M., Ryman, D. C., McDade, E., Jasielec, M. S., Buckles, V. D., Cairns, N. J., Fagan, A. M., Goate, A., Marcus, D. S., Xiong, C., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30229-0 · Cited by 121
The Synaptic Vesicle Glycoprotein 2: Structure, Function, and Disease Relevance
Stout, K. A., Dunn, A. R., Hoffman, C., & Miller, G. W. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00351 · Cited by 112
Stargardt, A., Swaab, D. F., & Bossers, K. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.08.014 · Cited by 109
Fu, C.-H., Iascone, D. M., Petrof, I., Hazra, A., Zhang, X., Pyfer, M. S., Tosi, U., Corbett, B. F., Cai, J., Lee, J., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.05.101 · Cited by 107
Ahnaou, A., Moechars, D., Raeymaekers, L., Biermans, R., Manyakov, N. V., Bottelbergs, A., Wintmolders, C., Van Kolen, K., Van De Casteele, T., Kemp, J. A., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-13839-6 · Cited by 98
The Gastrointestinal Tract Microbiome and Potential Link to Alzheimer’s Disease
Hill, J. M., Bhattacharjee, S., Pogue, A. I., & Lukiw, W. J. (2014) · Frontiers in Neurology · doi:10.3389/fneur.2014.00043 · Cited by 98
“to more favorable clinical outcomes (30, 48, 49).”
BackgroundCattaud, V., Bezzina, C., Rey, C. C., Lejards, C., Dahan, L., & Verret, L. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.024 · Cited by 88
Reyes-Marin, K. E., & Nuñez, A. (2017) · Brain Research · doi:10.1016/j.brainres.2017.09.026 · Cited by 84
“Furthermore, these seizures may be a critical part of AD pathogenesis (Scarmeas et al., 2009; Vossel et al., 2013).”
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Self-citationAlbuquerque, M. S., Mahar, I., Davoli, M. A., Chabot, J.-G., Mechawar, N., Quirion, R., & Krantic, S. (2015) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2015.00030 · Cited by 71
“Most importantly, levetiracetam has proven efficient in the management of not only spontaneous epileptiform activity, which accompanies the early stages of AD (Vossel et al., 2013), but also in improving cognition (Bakker et al., 2012).”
BackgroundAn Unbalanced Synaptic Transmission: Cause or Consequence of the Amyloid Oligomers Neurotoxicity?
Sciaccaluga, M., Megaro, A., Bellomo, G., Ruffolo, G., Romoli, M., Palma, E., & Costa, C. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115991 · Cited by 70
Tau-induced pathology in epilepsy and dementia: notions from patients and animal models.
Sánchez, M., García-Cabrero, A., Sánchez-Elexpuru, G., Burgos, D., & Serratosa, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041092 · Cited by 68
Masurkar, A. V. (2018) · Journal of Alzheimer’s Disease & Parkinsonism · doi:10.4172/2161-0460.1000412 · Cited by 68
“What could underlie a selective vulnerability of the ventral hippocampus/ventral CA1? Aberrant network excitability has been proposed as a potential factor in AD [68,69] and the relative hyper excitability of ventral neurons could make them more prone to neurotoxic epileptiform activity or activity-dependent worsening…”
BackgroundHippocampal Deficits in Amyloid-β-Related Rodent Models of Alzheimer’s Disease
Vyas, Y., Montgomery, J. M., & Cheyne, J. E. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00266 · Cited by 66
Ribarič, S. (2023) · Biomedicines · doi:10.3390/biomedicines11020355 · Cited by 66
Network dysfunction in α‐synuclein transgenic mice and human Lewy body dementia
Morris, M., Sanchez, P. E., Verret, L., Beagle, A. J., Guo, W., Dubal, D., Ranasinghe, K. G., Koyama, A., Ho, K., Yu, G., et al. (2015) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.257 · Cited by 61
Self-citationSelective lowering of synapsins induced by oligomeric α-synuclein exacerbates memory deficits
Larson, M. E., Greimel, S. J., Amar, F., LaCroix, M., Boyle, G., Sherman, M. A., Schley, H., Miel, C., Schneider, J. A., Kayed, R., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704698114 · Cited by 61
Malkov, A., Popova, I., Ivanov, A., Jang, S.-S., Yoon, S. Y., Osypov, A., Huang, Y., Zilberter, Y., & Zilberter, M. (2021) · Communications Biology · doi:10.1038/s42003-021-02551-x · Cited by 59
Algamal, M., Russ, A. N., Miller, M. R., Hou, S. S., Maci, M., Munting, L. P., Zhao, Q., Gerashchenko, D., Bacskai, B. J., & Kastanenka, K. V. (2022) · Communications Biology · doi:10.1038/s42003-022-04268-x · Cited by 50
Mechanisms of tau and Aβ-induced excitotoxicity
Pallo, S. P., DiMaio, J., Cook, A., Nilsson, B., & Johnson, G. V. W. (2016) · Brain Research · doi:10.1016/j.brainres.2015.12.048 · Cited by 46
Astrocytic and neuronal apolipoprotein E isoforms differentially affect neuronal excitability
Konings, S. C., Torres-Garcia, L., Martinsson, I., & Gouras, G. K. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.734001 · Cited by 43
“Although most studies support ApoE4-induced hyperexcitability, conflicting data have also been published showing, for example, reduced neuronal activity in ApoE4 mice (Wang et al., 2005).”
BackgroundTargeting neurodegeneration to prevent post-traumatic epilepsy.
Ali, I., Silva, J. C., Liu, S., Shultz, S. R., Kwan, P., Jones, N. C., & O'Brien, T. J. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.006 · Cited by 38
Bhattacharjee, S., Zhao, Y., & Lukiw, W. J. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00116 · Cited by 34
Miyamoto, T., Kim, D., Knox, J. A., Johnson, E., & Mucke, L. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.666529 · Cited by 33
Self-citationCell death assays for neurodegenerative disease drug discovery
Linsley, J. W., Reisine, T., & Finkbeiner, S. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1623784 · Cited by 32
Peters, S. T., Fahrenkopf, A., Choquette, J. M., Vermilyea, S. C., Lee, M. K., & Vossel, K. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00563 · Cited by 29
“oldest age group, epileptiform activity during NREM sleep persisted [A53T: χ(2)(2) = 11.”
BackgroundSelf-citationLomoio, S., Pandey, R. S., Rouleau, N., Menicacci, B., Kim, W., Cantley, W. L., Haydon, P. G., Bennett, D. A., Young-Pearse, T. L., Carter, G. W., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02147-3 · Cited by 25
Brain rhythm attractor breakdown in Alzheimer’s disease: Functional and pathologic implications
Karageorgiou, E., & Vossel, K. A. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.02.003 · Cited by 21
“[109] Vossel KA, Beagle AJ, Rabinovici GD, Shu H, Lee SE, Naasan G,”
BackgroundSelf-citationDas, M., Mao, W., Shao, E., Tamhankar, S., Yu, G.-Q., Yu, X., Ho, K., Wang, X., Wang, J., & Mucke, L. (2021) · iScience · doi:10.1016/j.isci.2021.103245 · Cited by 21
Self-citationAPOE4 Promotes Tonic-Clonic Seizures, an Effect Modified by Familial Alzheimer’s Disease Mutations
Lamoureux, L., Marottoli, F. M., Tseng, K. Y., & Tai, L. M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.656521 · Cited by 21
Mueller, S. G., & Weiner, M. W. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00418 · Cited by 12
Metadata
- Authors
- Vossel, K. A., Beagle, A. J., Rabinovici, G. D., Shu, H., Lee, S. E., Naasan, G., Hegde, M., Cornes, S. B., Henry, M. L., Nelson, A. B., Seeley, W. W., Geschwind, M. D., Gorno-Tempini, M. L., Shih, T., Kirsch, H. E., Garcia, P. A., Miller, B. L., & Mucke, L.
- Venue
- JAMA Neurology
- Publisher
- American Medical Association (AMA)
- Published
- 2013-09-01
- Volume
- 70
- Issue
- 9
- Pages
- 1158
- ISSN
- 2168-6149 (ISSN-L)
- OpenAlex
- W1970910654
- Cited by
- 741
- References
- 51
- FWCI
- 25.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.